ArticleBMC cancer2020

Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.

Seonyoung Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.